All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, August 10, 2022
Home » Blogs » BioWorld MedTech Perspectives » Coverage of coverage: two recent moves by CMS

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Coverage of coverage: two recent moves by CMS

Nov. 7, 2013
By Mark McCarty
No Comments

Continental_Currency_One-Third-Dollar_17-Feb-76_obv
A third of a dollar isn't what it used to be, is it?

When it comes to coverage and reimbursement, there are gatekeepers all over the place, but some keep bigger gates than others. Following are two stories about the Centers for Medicare & Medicaid Services and how it has kept its gate in recent weeks.

CMS not wild about MILD

CMS recently took it upon itself to review percutaneous, image-guided lumbar decompression for stenosis, proposing on Oct. 17 that it sees the evidence as insufficient to prompt coverage.

Among the references found in the coverage proposal is one addressing the MILD procedure by Vertos Medical, a company that is no doubt pulling out all the stops to get CMS on board. The agency said most of the evidence in support was provided by case series, and the only randomized, controlled trial “had a small enrollment and major design flaws.”

CMS also said it has “questions about missing information, questions about adverse events and conflicts of interest,” concluding that the evidence “does not support a conclusion of improved health outcomes.”

So it doesn’t look good. Still, we might bear in mind that more than 100 people sounded off on the treatment, the vast majority of which were supportive. Even if CMS passes, this won’t be the last we hear of MILD and PILD.

Heart failure? VAD you asked

CMS also recently published a coverage memo for ventricular assist devices, which among other things declared the Intermacs registry a dinosaur. The problem here is that the age of mammals has yet to arrive where a replacement registry is concerned, so T. Rex reigns until further notice.

Perhaps the most significant aspect of this coverage memo is that CMS seems to have pried open enough space for those bridge-to-decision patients with a passage stating that the agency has removed the word “permanent” from the language dealing with VAD for destination therapy.

Doctors seem to be of the view that CMS left a lot of ambiguity in its rewrite of the coverage manual, and the term “destination therapy” will now include a much more varied population. Still, where there’s fuzziness, there’s latitude, and what was a bad state of limbo for some heart failure patients now becomes a haven, and the docs have to deal with limbo, which frankly is a task they’re paid to handle.

All in all, it sounds like an improvement for heart failure patients, and an especially welcome bit of news for a patient population that is in desperate straits.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 9, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 9, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing